Participants 0 92 4
Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion
Participants 109 214 4
Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
Participants 301 364 3
visual function in symptomatic VMA/vitreomacular traction (VMT)
Participants 422 653 4
To determine the impact of intravitreal ocriplasmin on patient-reported visual function using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) during a 6-month follow-up in patients with symptomatic VMA
Participants 918 1031 7
A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 Î¼m or smalle
Participants 1131 1164 3
 Patients with symptomatic VMA/VM
Participants 1690 1723 5
es, 464 patients received ocripla
Participants 1728 1748 5
and 188 received pla
Participants 2804 2917 3
day 28.
CONCLUSIONS AND RELEVANCE Ocriplasmin produces clinically meaningful improvement in patient-reported visu
